Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults.
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 13 Mar 2012 The vaccine showed immunogenicity and favourable safety profile, according to Astellas Pharma and UMN Pharma media release
- 20 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2011 Astellas confirms in a company media release that vaccine administration has been successfully completed.